Overall, there are 25 ongoing clinical trials targeting neuroinflammation in AD: four in phase 1, 19 in phase 2, and two in phase 3 [masitinib (tyrosine-kinase inhibitor) and NE3107 (insulin-sensitizing agent)]. The gene discussed is INS; the disease is Alzheimer disease.